The 13th International AIDS Society Conference on HIV Science (IAS 2025) took place in Kigali, Rwanda. While much of the meeting was dedicated to mounting responses to the global HIV funding crisis, drug innovation continues to move forward. Most importantly, there is an emphasis on prevention and treatment simplification: Providing options that are as user-friendly as possible.
While talk about injectables continues, another exciting avenue in drug development is longer-acting oral formulations, for both prevention and treatment. In some ways, this may be the “holy grail” of drug regimens for those who do not want injections, and who may struggle with adherence.
Considering the lackluster rollout of both long-acting injectable prevention and long-acting injectable treatment products for HIV, there was palpable anticipation from audiences at IAS 2025 interested in longer-acting oral options for both prevention and treatment.
Read the full news story at TheBodyPro.
All TheBodyPro reports from IAS 2025 can be accessed here.
Source : TheBodyPro
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.